Submit Manuscript  

Article Details


A Review of Research Progress on Agathis dammara and its Application Prospects for Cardiovascular Diseases and Fatty Liver Disease

Author(s):

Anyi Wang, Shanshan Yue, Ankang Peng and Rong Qi*   Pages 1 - 7 ( 7 )

Abstract:


Cardiovascular diseases and fatty liver disease have become the leading causes of death in modern society. However, currently existing drugs do not solve all issues related to these diseases; thus, it is expected that more potential drugs for clinical use will be developed. Undeniably, natural products have attracted increasing attention. It is of great significance to identify effective active monomer components for drug discovery and disease prevention. As a pure natural product, Agathis dammara (AD) has antioxidant, hypolipidemic, hypoglycemic, antitumor and anti-inflammatory activities. However, at present, there are few reports regarding the effects of AD on chronic inflammatory cardiovascular diseases such as aneurysm, atherosclerosis, myocardial ischemia-reperfusion injury, and cardiac hypertrophy and liver diseases such as fatty liver disease. AD and products derived from it have very broad application prospects for cardiovascular diseases and fatty liver disease.

Keywords:

Agathis dammara, application prospects, cardiovascular diseases, fatty liver disease, antioxidant, anti-inflammatory

Affiliation:

Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, 38 Xueyuan Road, Beijing 100191, Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, 38 Xueyuan Road, Beijing 100191, Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, 38 Xueyuan Road, Beijing 100191, Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, 38 Xueyuan Road, Beijing 100191



Read Full-Text article